An open-label pilot trial assessing tolerability and feasibility of LSD microdosing in patients with major depressive disorder (LSDDEP1)

An open-label pilot trial assessing tolerability and feasibility of LSD microdosing in patients with major depressive disorder (LSDDEP1)

Abstract Background Globally, an estimated 260 million people suffer from depression [1], and there is a clear need for the development of new, alternative antidepressant therapies. In light of problems with the tolerability and efficacy of available treatments [2], a global trend is emerging for pa...

Full description

Bibliographic Details
Main Authors: Carina Joy Donegan, Dimitri Daldegan-Bueno, Rachael Sumner, David Menkes, William Evans, Nicholas Hoeh, Frederick Sundram, Lisa Reynolds, Rhys Ponton, Alana Cavadino, Todd Smith, Partha Roop, Nathan Allen, Binu Abeysinghe, Darren Svirskis, Anna Forsyth, Mahima Bansal, Suresh Muthukumaraswamy
Format: Article
Language:English
Published: BMC 2023-10-01
Series:Pilot and Feasibility Studies
Subjects:
Microdosing
Lysergic acid diethylamide
Psychedelics
Major depressive disorder
Online Access:https://doi.org/10.1186/s40814-023-01399-8

Internet

https://doi.org/10.1186/s40814-023-01399-8

Similar Items